Cargando…
Case Report: No Response to Liposomal Daunorubicin in a Patient with Drug-Resistant HIV-Associated Visceral Leishmaniasis
Visceral leishmaniasis (VL) in patients with HIV co-infection presents a significant therapeutic challenge due to the lessened chance of achieving long-term cure. We report a case of VL in a 60-year-old man with HIV infection who became refractory to anti-leishmania treatment due to multi-drug resis...
Autores principales: | Gow, Nicholas J., Davidson, Robert N., Ticehurst, Rob, Burns, Andrew, Thomas, Mark G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549335/ https://www.ncbi.nlm.nih.gov/pubmed/26305562 http://dx.doi.org/10.1371/journal.pntd.0003983 |
Ejemplares similares
-
Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007) -
Drug Resistance in Visceral Leishmaniasis
por: Maltezou, Helena C.
Publicado: (2010) -
Evaluating drug resistance in visceral leishmaniasis: the challenges
por: HENDRICKX, S, et al.
Publicado: (2018) -
Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016) -
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)